Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes - PubMed (original) (raw)

Randomized Controlled Trial

. 2018 Mar;43(4):891-899.

doi: 10.1038/npp.2017.282. Epub 2017 Nov 20.

Affiliations

Randomized Controlled Trial

Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes

Karl Mann et al. Neuropsychopharmacology. 2018 Mar.

Abstract

Randomized trials of medications for alcohol dependence (AD) often report no differences between active medications. Few studies in AD have tested hypotheses regarding which medication will work best for which patients (ie, precision medicine). The PREDICT study tested acamprosate and naltrexone vs placebo in 426 randomly assigned AD patients in a 3-month treatment. PREDICT proposed individuals whose drinking was driven by positive reinforcement (ie, reward drinkers) would have a better treatment response to naltrexone, whereas individuals whose drinking was driven by negative reinforcement (ie, relief drinkers) would have a better treatment response to acamprosate. The goal of the current analysis was to test this precision medicine hypothesis of the PREDICT study via analyses of subgroups. Results indicated that four phenotypes could be derived using the Inventory of Drinking Situations, a 30-item self-report questionnaire. These were high reward/high relief, high reward/low relief, low reward/high relief, and low reward/low relief phenotypes. Construct validation analyses provided strong support for the validity of these phenotypes. The subgroup of individuals who were predominantly reward drinkers and received naltrexone vs placebo had an 83% reduction in the likelihood of any heavy drinking (large effect size). Cutoff analyses were done for clinical applicability: individuals are reward drinkers and respond to naltrexone if their reward score was higher than their relief score AND their reward score was between 12 and 31. Using naltrexone with individuals who are predominantly reward drinkers produces significantly higher effect sizes than prescribing the medication to a more heterogeneous sample.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Annis HM, Graham JM, Davis CS (1987) Inventory of Drinking Situations: User’s Guide. Addiction Research Foundation: Toronto, ON, Canada.
    1. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003–2017. - PubMed
    1. Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL et al (2012). The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders. Neuropsychopharmacology 37: 402–411. - PMC - PubMed
    1. Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. Psychological Corporation: San Antonio, TX, USA.
    1. Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975–990. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources